

PMCF Plan Template as per Medical Device Regulation (EU) 2017/745 (MDR) part B of Annex XIV

PMCF plan number:	PMCF plan date:	PMCF plan version:	
REVISION HISTORY			
Rev	Revision date	Description of Change	Revised by

SECTION A. MANUFACTURER CONTACT DETAILS
Legal manufacturers name:
Person responsible for regulatory compliance:
Contact person for PMCF
E-mail:

SECTION B. MEDICAL DEVICE DESCRIPTION AND SPECIFICATION
Product or trade name:
List and description of any variants Wand/or configurations covered by this plan:

SECTION C. ACTIVITIES RELATED TO PMCF: GENERAL AND SPECIFIC METHODS AND PROCEDURES	
<i>(tick all that apply and complete a different subsection for each e.g C.1 C.2, ...)</i>	
<input type="checkbox"/>	Device registry
<input type="checkbox"/>	PMCF studies
<input type="checkbox"/>	Real-world evidence
<input type="checkbox"/>	Surveys
<input type="checkbox"/>	A review of relevant retrospective data from patients previously exposed to the device.
<input type="checkbox"/>	The extended follow-up of patients enrolled in premarket investigations
<input type="checkbox"/>	Other (explain)

SECTION C. 1 DESCRIPTION OF ACTIVITY		Details / explanation & Justifications
Clearly stated research question		
Objective <i>(tick all that apply)</i>		
<input type="checkbox"/>	Confirming the safety of the device throughout its expected lifetime	
<input type="checkbox"/>	Confirming the performance of the device throughout its expected lifetime	
<input type="checkbox"/>	Identifying previously unknown side-effects (related to the procedures or to the medical devices)	
<input type="checkbox"/>	Monitoring the identified side-effects and contraindications	
<input type="checkbox"/>	Identifying and analysing emergent risks on the basis of factual evidence	
<input type="checkbox"/>	Ensuring the continued acceptability of the benefit-risk ratio	
<input type="checkbox"/>	Identifying possible systematic misuse or off-label use of the device, with a view to verify that the intended purpose is correct.	
<input type="checkbox"/>	An analysis of a larger study population – (e.g. more health centres, more countries, increase in diversity of age / race)	
Describe the different procedures which will be used as part of PMCF		
<input type="checkbox"/>	Survey from health care professional	(attached a copy of the planned survey to this plan)
<input type="checkbox"/>	Survey from patients/users	(attached a copy of the planned survey to this plan)
<input type="checkbox"/>	Collecting data in registries	
<input type="checkbox"/>	Review of case reports which may reveal misuse or off-label use	
<input type="checkbox"/>	Screening of scientific literature and other sources of clinical data	
<input type="checkbox"/>	Post-market studies	

The clinical investigation plan/study plan should identify and where needed justify at a minimum: <i>(The points below may not all apply to a retrospective data review)</i>	Justifications
• the study population (corresponding to the CE-mark scope)	
• inclusion/exclusion criteria;	
• rational and justification of the chosen study design including use of controls/control groups (where relevant; randomised or not)	
• the selection of sites and investigators;	
• related study endpoints	
• statistical considerations	
• the number of subjects involved	
• the duration of patient follow-up	
• the data to be collected	
• the analysis plan including any interim reporting where appropriate to ensure continuous risk management based on clinical data;	

<ul style="list-style-type: none"> procedures/criteria for early study termination 	
<ul style="list-style-type: none"> ethical considerations 	
<ul style="list-style-type: none"> methods of quality control of data where appropriate 	

SECTION C. 2 (IF APPLICABLE) <i>(copy table C1 below and complete)</i>	Details / explanation
Clearly stated research question	

SECTION D. REFERENCE TO THE RELEVANT PARTS OF THE TECHNICAL DOCUMENTATION
Clinical Evaluation Report (date and version)
Risk Management File (date and version)

SECTION E. EVALUATION OF CLINICAL DATA RELATING TO EQUIVALENT OR SIMILAR DEVICES
<p>The manufacturer shall gather in this section information regarding equivalent / similar devices for which clinical data will be further evaluated and presented in the PMCF report.</p> <p>Please note that PMCF data intended to demonstrate continuing safety and performance should be sourced from the device under evaluation.</p> <p>Data from equivalent or similar devices may be used, for example to update the information relating to the state of the art, to identify and further assess relevant safety outcomes etc.</p> <p>The selected devices shall be consistent throughout the technical documentation submitted for CE approval</p>

SECTION F. REFERENCE TO ANY APPLICABLE COMMON SPECIFICATION(S), HARMONIZED STANDARD(S) OR APPLICABLE GUIDANCE DOCUMENT(S)
<p>Common specification(s) to comply with, if applicable: (Title, date and version)</p> <p>Harmonised standards to apply, if applicable (Title, date and version)</p> <p>Guidance on PMCF, if applicable</p> <p>Regulatory or Specific guidance identifying benchmark requirements for the device type , if applicable</p>

SECTION G. – ESTIMATED DATE OF THE PMCF EVALUATION REPORT
When the manufacturer plans to have the first report. The timelines shall be defined quarterly or at least yearly.

MANUFACTURERS APPROVAL OF THE PMCF PLAN	
Name:	Signature:
Position:	Date: